Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071

ABSTRACT GS 4071 is a potent carbocyclic transition-state analog inhibitor of influenza virus neuraminidase with activity against both influenza A and B viruses in vitro. GS 4116, the guanidino analog of GS 4071, is a 10-fold more potent inhibitor of influenza virus replication in tissue culture than GS 4071. In this study we determined the oral bioavailabilities of GS 4071, GS 4116, and their respective ethyl ester prodrugs in rats. Both parent compounds and the prodrug of the guanidino analog exhibited poor oral bioavailability (2 to 4%) and low peak concentrations in plasma (Cmaxs; Cmax<0.06 μg/ml). In contrast, GS 4104, the ethyl ester prodrug of GS 4071, exhibited good oral bioavailability (35%) as GS 4071 and high Cmaxs of GS 4071 (Cmax = 0.47 μg/ml) which are 150 times the concentration necessary to inhibit influenza virus neuraminidase activity by 90%. The bioavailability of GS 4104 as GS 4071 was also determined in mice (30%), ferrets (11%), and dogs (73%). The plasma of all four species exhibited high, sustained concentrations of GS 4071 such that at 12 h postdosing the concentrations of GS 4071 in plasma exceeded those necessary to inhibit influenza virus neuraminidase activity by 90%. These results demonstrate that GS 4104 is an orally bioavailable prodrug of GS 4071 in animals and that it has the potential to be an oral agent for the prevention and treatment of influenza A and B virus infections in humans.

[1]  A. Langmuir,et al.  The Thucydides syndrome. A new hypothesis for the cause of the plague of Athens. , 1985, The New England journal of medicine.

[2]  D. M. Ryan,et al.  GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets , 1995, Antimicrobial agents and chemotherapy.

[3]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[4]  V. Stella,et al.  Prodrugs , 1985, Drugs.

[5]  P. Palese,et al.  Variation in Influenza Virus Genes , 1989 .

[6]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[7]  D. Barnard,et al.  Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. , 1998, Antiviral research.

[8]  R. Sidwell,et al.  Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection , 1998, Antimicrobial Agents and Chemotherapy.

[9]  F J Leinweber,et al.  Possible physiological roles of carboxylic ester hydrolases. , 1987, Drug metabolism reviews.

[10]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[11]  R. Couch.  Advances in Influenza Virus Vaccine Research a , 1993, Annals of the New York Academy of Sciences.

[12]  C A Dawson,et al.  First‐Pass Uptake of Verapamil, Diazepam, and Thiopental in the Human Lung , 1989, Anesthesia and analgesia.

[13]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[14]  G. Air,et al.  Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding , 1995, Journal of virology.

[15]  C Y Quon,et al.  Species differences in the stereoselective hydrolysis of esmolol by blood esterases. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[16]  G. Air,et al.  Influenza virus neuraminidase with hemagglutinin activity. , 1984, Virology.

[17]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[18]  H. Klenk,et al.  The Molecular Biology of Influenza Virus Pathogenicity , 1988, Advances in Virus Research.

[19]  F. Newman,et al.  Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. , 1989, The Journal of infectious diseases.

[20]  R. Compans,et al.  Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. , 1976, The Journal of general virology.

[21]  A. Kendal,et al.  Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. , 1987, American journal of public health.

[22]  F. Hayden,et al.  Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. , 1992, Current topics in microbiology and immunology.

[23]  D. M. Ryan,et al.  Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) , 1994, Antimicrobial Agents and Chemotherapy.

[24]  Glyn Taylor,et al.  The absorption and metabolism of xenobiotics in the lung , 1990 .

[25]  D. Rotella.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity , 1997 .

[26]  R. Compans,et al.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.

[27]  D. M. Ryan,et al.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro , 1993, Antimicrobial Agents and Chemotherapy.

[28]  K. Cundy,et al.  Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104 , 1997, Antimicrobial agents and chemotherapy.

[29]  R. Sidwell,et al.  GS 4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B viruses in vitro , 1997 .

[30]  Burnet Fm.  Mucins and Mucoids in relation to Influenza Virus Action. IV. Inhibition by Purified Mucoid of Infection and Haemagglutination with the Virus Strain WSE. , 1948 .

[31]  B. Jin,et al.  The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor. , 1994, Carbohydrate research.

[32]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[33]  F. Burnet,et al.  Mucins and mucoids in relation to influenza virus action; general discussion. , 1948, The Australian journal of experimental biology and medical science.

[34]  J. Pennington.  Respiratory infections : diagnosis and management , 1995 .